SGMT · Sagimet Biosciences Inc. Series A Common Stock
View on chartInsiders & Stakes
| NEW ENTERPRISE ASSOCIATES 13 LP 10% Owner | ▼ Sell | Other | 3,000,275 Shares held | 1/29/2024 | View profile |
| KPCB PBD Associates, LLC 10% Owner | ▼ Sell | Other | 1,899,475 Shares held | 7/18/2023 | View profile |
| Wu Jinzi Jason Director | ▼ Sell | Other | 1,654,701 Shares held | 7/18/2023 | View profile |
| David Happel President & CEO | ▼ Sell | Open Market | 741,570 Shares held | 7/20/2026 | View profile |
| Elizabeth Rozek General Counsel and CCO | ▼ Sell | Open Market | 224,414 Shares held | 7/20/2026 | View profile |
| Eduardo Bruno Martins Chief Medical Officer | ▲ Buy | Grant | 147,296 Shares held | 2/19/2026 | View profile |
| George Kemble Executive Chairman | ▼ Sell | Open Market | 62,161 Shares held | 8/14/2026 | View profile |
| Thierry Chauche Chief Financial Officer | ▲ Buy | Grant | 59,688 Shares held | 2/19/2026 | View profile |
| Beth C. Seidenberg Director | ▲ Buy | Open Market | 46,875 Shares held | 7/18/2023 | View profile |
| KERINS PATRICK J 10% Owner | ▼ Sell | Other | 13,139 Shares held | 1/29/2024 | View profile |
| Parsey Merdad Director | ▼ Sell | Other | 12,794 Shares held | 7/18/2023 | View profile |
| BASKETT FOREST 10% Owner | ▼ Sell | Other | 11,300 Shares held | 1/29/2024 | View profile |
| Scott D. Sandell 10% Owner | ▼ Sell | Other | 6,997 Shares held | 1/29/2024 | View profile |
| NEA Partners 13, Limited Partnership 10% Owner | ▼ Sell | Other | 0 Shares held | 1/29/2024 | View profile |
Transaction History
| George Kemble | ▲ Buy | Option Exercise | 326,618 | $2.1M | 8/14/2026 |
| George Kemble | ▲ Buy | Option Exercise | 24,369 | $155K | 8/14/2026 |
| George Kemble | ▼ Sell | Open Market | 350,987 | $3.6M | 8/14/2026 |
| George Kemble | ▲ Buy | Option Exercise | 9,751 | $62K | 8/11/2026 |
| George Kemble | ▲ Buy | Option Exercise | 10,455 | $66K | 8/11/2026 |
| George Kemble | ▼ Sell | Open Market | 20,206 | $201K | 8/11/2026 |
| David Happel | ▼ Sell | Open Market | 64,051 | $497K | 7/20/2026 |
| Elizabeth Rozek | ▼ Sell | Open Market | 10,545 | $82K | 7/20/2026 |
| George Kemble | ▼ Sell | Open Market | 18,844 | $141K | 7/20/2026 |
| Elizabeth Rozek | ▲ Buy | Grant | 44,000 | $0 | 2/19/2026 |
| Eduardo Bruno Martins | ▲ Buy | Grant | 44,000 | $0 | 2/19/2026 |
| David Happel | ▲ Buy | Grant | 128,000 | $0 | 2/19/2026 |
| Thierry Chauche | ▲ Buy | Grant | 44,000 | $0 | 2/19/2026 |
| David Happel | ▼ Sell | Open Market | 12,101 | $65K | 2/10/2026 |
| Thierry Chauche | ▼ Sell | Open Market | 1,312 | $7K | 2/10/2026 |
| Eduardo Bruno Martins | ▼ Sell | Open Market | 3,640 | $20K | 2/10/2026 |
| Elizabeth Rozek | ▼ Sell | Open Market | 2,622 | $14K | 2/10/2026 |
| George Kemble | ▼ Sell | Open Market | 37,688 | $290K | 11/20/2025 |
| Elizabeth Rozek | ▲ Buy | Grant | 9,855 | $0 | 11/4/2025 |
| David Happel | ▼ Sell | Open Market | 65,478 | $598K | 7/21/2025 |
| Eduardo Bruno Martins | ▼ Sell | Open Market | 8,277 | $76K | 7/21/2025 |
| Elizabeth Rozek | ▼ Sell | Open Market | 10,780 | $98K | 7/21/2025 |
| Eduardo Bruno Martins | ▲ Buy | Grant | 34,000 | $0 | 2/6/2025 |
| David Happel | ▲ Buy | Grant | 116,000 | $0 | 2/6/2025 |
| Elizabeth Rozek | ▲ Buy | Grant | 34,000 | $0 | 2/6/2025 |
| Thierry Chauche | ▲ Buy | Grant | 17,000 | $0 | 2/6/2025 |
| George Kemble | ▼ Sell | Open Market | 23,625 | $75K | 7/23/2024 |
| Eduardo Bruno Martins | ▼ Sell | Open Market | 8,357 | $26K | 7/19/2024 |
| Elizabeth Rozek | ▼ Sell | Open Market | 10,914 | $34K | 7/19/2024 |
| George Kemble | ▼ Sell | Open Market | 14,062 | $44K | 7/19/2024 |
| David Happel | ▲ Buy | Open Market | 12,100 | $64K | 3/26/2024 |
| NEA Partners 13, Limited Partnership | ▼ Sell | Other | 850,000 | $0 | 1/29/2024 |
| NEW ENTERPRISE ASSOCIATES 13 LP | ▼ Sell | Other | 850,000 | $0 | 1/29/2024 |
| NEA Partners 13, Limited Partnership | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 |
| BASKETT FOREST | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 |
| NEA Partners 13, Limited Partnership | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 |
| Scott D. Sandell | ▼ Sell | Other | 850,000 | $0 | 1/29/2024 |
| Scott D. Sandell | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 |
| KERINS PATRICK J | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 |
| KERINS PATRICK J | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 |
| BASKETT FOREST | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 |
| BASKETT FOREST | ▼ Sell | Other | 11,300 | $0 | 1/29/2024 |
| Scott D. Sandell | ▼ Sell | Other | 260,950 | $0 | 1/29/2024 |
| Scott D. Sandell | ▼ Sell | Other | 6,997 | $0 | 1/29/2024 |
| KERINS PATRICK J | ▼ Sell | Other | 850,000 | $0 | 1/29/2024 |
| KERINS PATRICK J | ▼ Sell | Other | 13,139 | $0 | 1/29/2024 |
| BASKETT FOREST | ▼ Sell | Other | 850,000 | $0 | 1/29/2024 |
| David Happel | ▲ Buy | Open Market | 1,600 | $7K | 12/7/2023 |
| Eduardo Bruno Martins | ▲ Buy | Grant | 89,570 | $0 | 11/17/2023 |
| David Happel | ▲ Buy | Grant | 624,910 | $0 | 11/17/2023 |
| Elizabeth Rozek | ▲ Buy | Grant | 171,420 | $0 | 11/17/2023 |
| George Kemble | ▲ Buy | Grant | 150,750 | $0 | 11/17/2023 |
| David Happel | ▲ Buy | Open Market | 590 | $1K | 11/16/2023 |
| George Kemble | ▲ Buy | Option Exercise | 5,630 | $4K | 9/7/2023 |
| NEW ENTERPRISE ASSOCIATES 13 LP | ▲ Buy | Open Market | 30,000 | $480K | 7/18/2023 |
| Beth C. Seidenberg | ▼ Sell | Other | 38,763 | — | 7/18/2023 |
| Beth C. Seidenberg | ▲ Buy | Open Market | 46,875 | $750K | 7/18/2023 |
| Beth C. Seidenberg | ▼ Sell | Other | 1,860,712 | — | 7/18/2023 |
| Parsey Merdad | ▼ Sell | Other | 8,677 | — | 7/18/2023 |
| Beth C. Seidenberg | ▼ Sell | Other | 84,768 | — | 7/18/2023 |
| Beth C. Seidenberg | ▲ Buy | Grant | 38,763 | — | 7/18/2023 |
| KPCB PBD Associates, LLC | ▼ Sell | Other | 1,860,712 | — | 7/18/2023 |
| Wu Jinzi Jason | ▼ Sell | Other | 1,654,701 | — | 7/18/2023 |
| KPCB PBD Associates, LLC | ▼ Sell | Other | 38,763 | — | 7/18/2023 |
| NEW ENTERPRISE ASSOCIATES 13 LP | ▼ Sell | Open Market | 662 | $11K | 7/18/2023 |
| Parsey Merdad | ▼ Sell | Other | 4,117 | — | 7/18/2023 |
| NEW ENTERPRISE ASSOCIATES 13 LP | ▼ Sell | Other | 3,769,857 | — | 7/18/2023 |
| Parsey Merdad | ▲ Buy | Grant | 8,677 | — | 7/18/2023 |
| NEW ENTERPRISE ASSOCIATES 13 LP | ▼ Sell | Other | 37,676 | — | 7/18/2023 |
| NEW ENTERPRISE ASSOCIATES 13 LP | ▼ Sell | Other | 13,404 | $11K | 7/18/2023 |
| NEW ENTERPRISE ASSOCIATES 13 LP | ▼ Sell | Other | 37,676 | — | 7/18/2023 |
| KPCB PBD Associates, LLC | ▼ Sell | Other | 38,763 | — | 7/18/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Goldman Sachs reinstates Sell rating on SGMT with $7 target
Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.
Goldman Sachs reinstates Sell rating on SGMT with $7 target. Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.